Showing results (1-10 of 123) with videos related to
Sort By:
Pageof 13
Biological & Pharmaceutical Bulletin|July 5, 2022
Therapeutic Drug Monitoring of Antibody DrugsAtsushi YonezawaBiological & Pharmaceutical Bulletin|July 2, 2025
Identification and Physiological Analysis of Novel Riboflavin Transporter RFVTAtsushi YonezawaYakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|November 6, 2012
[Platinum agent-induced nephrotoxicity via organic cation transport system]Atsushi YonezawaPharmacology & Therapeutics|October 18, 2021
Recent advances in riboflavin transporter RFVT and its genetic diseaseCongyun Jin, Atsushi YonezawaGan to Kagaku Ryoho. Cancer & Chemotherapy|May 9, 2020
[Current Issues and Future Perspectives of Biosimilar in Cancer Therapy]Atsushi Yonezawa, Kazuo MatsubaraBiochemical Pharmacology|December 15, 2010
Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agentsAtsushi Yonezawa, Ken-Ichi InuiBritish Journal of Pharmacology|April 5, 2011
Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomicsAtsushi Yonezawa, Ken-ichi InuiMolecular Aspects of Medicine|March 20, 2013
Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52Atsushi Yonezawa, Ken-ichi InuiEuropean Journal of Pharmacology|April 17, 2013
Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse modelsHaruka Nakanishi, Atsushi Yonezawa, Kazuo Matsubara, et al.Journal of Pharmaceutical and Biomedical Analysis|November 18, 2018
Acceleration of nano-surface and molecular-orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of TocilizumabNoriko Iwamoto, Atsushi Yonezawa, Kazuo Matsubara, et al.Pageof 13